, Columnist
Crowded Migraine Market Puts Drugmakers to the Test
They’re always saying they care more about volume than price. Here’s a chance to prove it.
This article is for subscribers only.
The market for migraine medicines is getting better and better for patients. And for the companies that are crowding into it, it has the potential to be a drug-price proving ground.
The Food and Drug Administration approved Eli Lilly & Co.’s Emgality on Thursday, 13 days after it OK’ed Teva Pharmaceutical Industries Ltd.’s similar Ajovy, and less than five months after the first approval in the class, for Novartis AG and Amgen Inc.’s Aimovig.